Expanded use of minimally invasive mitral valve surgery will be the No. 2 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
It’s increasingly clear that there’s no good reason to delay surgical repair in patients with primary mitral valve disease and severe regurgitation. Two experts share perspectives about what that means in practice.
Ischemic mitral regurgitation is extremely difficult to manage. That’s why Dr. Deborah Kwon is intent on identifying imaging-based predictors of progression to enable earlier and wiser intervention.
This newly approved percutaneous therapy offers a minimally invasive option for mitral regurgitation patients at high risk from surgery. Ongoing studies aim to better define just which patients benefit.